Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
VERACYTE, INC. (VCYT) reported that Chief Financial Officer Rebecca Chambers sold common stock and had shares withheld for taxes. On September 4, 2026, she sold 2,477 shares at a weighted-average price of $42.8059 and 1,175 shares at $43.7140 in open-market or private transactions under a Rule 10b5-1 plan adopted on August 21, 2025. On September 2, 2026, 3,603 shares were withheld at $44.88 per share to satisfy tax withholding obligations upon vesting of restricted stock units and did not represent a sale.
VERACYTE, INC. (VCYT) reports that Annie McGuire, EVP and General Counsel, disposed of common stock in several transactions. On September 4, 2026, she sold 2,154 shares at a weighted average price of $42.79 and 1,100 shares at a weighted average price of $43.67, in open-market or private transactions made under a Rule 10b5-1 plan adopted on August 29, 2025. On September 2, 2026, 3,215 shares were withheld to satisfy tax obligations upon vesting of restricted stock units, which the company states does not represent a sale.
VERACYTE, INC. (VCYT) reported that Chief Executive Officer and director Marc Stapley had 8,782 shares of common stock withheld on September 2, 2026 to satisfy tax withholding obligations related to vesting restricted stock units; this is reported as a disposition but is explicitly described as not representing a sale.
Following this withholding, he directly holds 432,073 shares of Veracyte common stock, which includes 361 shares purchased on July 31, 2026 under the Veracyte, Inc. Employee Stock Purchase Plan. No Rule 10b5-1 trading plan is indicated for this tax-withholding transaction.
VERACYTE, INC. (VCYT) has a notice of proposed sale under Rule 144 filed on behalf of officer Ann McGuire. The notice covers the potential sale of 3,254 shares of Veracyte common stock through Morgan Stanley Smith Barney LLC, with an approximate sale date of September 4, 2026. The shares to be sold were acquired on September 2, 2026 as Restricted Stock Units from the issuer. The filing also lists Veracyte common shares outstanding as 80,390,731, which is a baseline figure, not the amount being sold.
VERACYTE, INC. (VCYT) is the issuer of common stock for which officer Rebecca Chambers has filed a notice of proposed resale under Rule 144. The notice covers up to 3,652 shares of common stock, associated with restricted stock units held for her account.
The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of approximately $163,134.84 and a proposed sale date of September 4, 2026 on Nasdaq.
Veracyte, Inc. (VCYT) received a Rule 144 notice that Philip Febbo plans to sell up to 13,110 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ market. The shares were acquired from Veracyte upon vesting of restricted stock units during the period from March 2, 2026 through September 2, 2026.
VERACYTE, INC. (VCYT) director Muna Bhanji reported selling 1,864 shares of common stock on September 1, 2026 at a price of $42.97 per share in an open-market or private transaction. After this sale, Bhanji directly holds 42,718 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 2, 2026.
VERACYTE, INC. (VCYT) is the issuer of common stock that Muna Bhanji plans to sell under Rule 144. The notice covers 3,728 shares of Veracyte common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value listed as $161,012.32 and a proposed sale date of September 1, 2026. The securities to be sold originated from Restricted Stock Units granted by the issuer with an acquisition date of June 18, 2026.
Veracyte reported strong Q2 2026 results, with total revenue rising 15% to $150.3 million, driven by 19% growth in testing revenue to $145.7 million as diagnostic test volume increased 14% to 48,389. Biopharmaceutical and other revenue declined after exiting French contract services.
Gross profit increased to $108.5 million from $89.8 million, and the company generated net income of $25.5 million (diluted EPS $0.31) versus a small loss a year earlier. For the first half of 2026, revenue grew 18% to $289.4 million and net income reached $54.2 million.
Cash, cash equivalents and short-term investments totaled $485.2 million at June 30, 2026, supported by $81.0 million of operating cash flow. Management is increasing research and development spending, especially on the TrueMRD platform and IVD expansion, while noting macroeconomic and reimbursement risks.
Veracyte, Inc. reported total revenue of $150.3 million for the quarter ended June 30, 2026, up 15% from $130.2 million a year earlier. Testing revenue grew 19% to $145.7 million, driven by Decipher prostate testing revenue of $91.9 million and Afirma revenue of $51.2 million. Test volumes increased 13% to 50,967, including 17% growth in Decipher tests to about 29,700 and 10% growth in Afirma tests to about 18,600.
GAAP net income was $25.5 million, a 17.0% margin and an improvement from a prior-year loss, with diluted EPS of $0.31. Non-GAAP gross margin rose to 75% and adjusted EBITDA reached $44.0 million, or 29.2% of revenue. The company generated $45.8 million of operating cash flow and ended the quarter with $485.2 million in cash, cash equivalents and short-term investments.
Management highlighted launches of the Prosigna Breast Test and the TrueMRD Monitoring Test for muscle-invasive bladder cancer, along with Medicare coverage for TrueMRD. Veracyte raised its 2026 total revenue outlook to $590–$596 million and testing revenue guidance to $576–$582 million, and continues to expect adjusted EBITDA margin above 26%.